BioRestorative Therapies, Inc. (BRTX)
NASDAQ: BRTX · Real-Time Price · USD
1.700
0.00 (0.00%)
Apr 29, 2025, 1:09 PM EDT - Market open
BioRestorative Therapies Employees
BioRestorative Therapies had 11 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
11
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$36,455
Profits / Employee
-$816,307
Market Cap
12.76M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
BRTX News
- 14 days ago - BioRestorative to Participate in Benzinga All-Access Show Today to Discuss Recent Achievements of Key Clinical & Regulatory Milestones, and Highlight Commercial Opportunities - GlobeNewsWire
- 19 days ago - BioRestorative Confirms No Material Impact from Reciprocal Tariffs; All BRTX-100 Production & Manufacturing Performed in the United States - GlobeNewsWire
- 4 weeks ago - BioRestorative Therapies, Inc. (BRTX) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - BioRestorative Announces FDA Clearance of IND for Phase 2 Trial of BRTX-100 in Chronic Cervical Discogenic Pain - GlobeNewsWire
- 2 months ago - BioRestorative Announces Updated Time for February 27th Webcasted Conference Call to Discuss Clinical Pipeline Update - GlobeNewsWire
- 2 months ago - BioRestorative Receives FDA Fast Track Designation for BRTX-100 Chronic Lumbar Disc Disease Program - GlobeNewsWire
- 5 months ago - BioRestorative Therapies Announces Notice of Allowance of Key New Patent Protecting ThermoStem® Metabolic Disease Program - GlobeNewsWire
- 5 months ago - BioRestorative Therapies, Inc. (BRTX) Q3 2024 Earnings Call Transcript - Seeking Alpha